Home › Research › Drug development
Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease
Serguei Nabirotchkin, Jan Bouaziz, Fabrice Glibert, Jonas Mandel, Julie Foucquier, Rodolphe Hajj, Noëlle Callizot, Nathalie Cholet et al.. Journal of Alzheimer's disease : JAD, 2022
Topic: Genetics and APOE
It enables robust identification of signaling pathways enriched in disease susceptibility loci. Therapeutic targeting of the disease-associated signaling networks provides a reliable way for rational drug repurposing and rapid development of synergistic drug combinations for common human diseases. Here we demonstrate the feasibility and efficacy of the proposed approach with an experiment application to Alzheimer's disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nabirotchkin, S., Bouaziz, J., Glibert, F., Mandel, J., Foucquier, J., Hajj, R., et al. (2022). Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-220120
Vancouver
Nabirotchkin S, Bouaziz J, Glibert F, Mandel J, Foucquier J, Hajj R, et al. Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2022. doi:10.3233/jad-220120. PMID: 35811522.
BibTeX
@article{nabirotchkin2022-35811522,
author = {Nabirotchkin, Serguei and Bouaziz, Jan and Glibert, Fabrice and Mandel, Jonas and Foucquier, Julie and Hajj, Rodolphe and Callizot, Noëlle and Cholet, Nathalie and others},
title = {{Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2022},
doi = {10.3233/jad-220120},
pmid = {35811522},
url = {https://doi.org/10.3233/jad-220120}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- It enables robust identification of signaling pathways enriched in disease susceptibility loci.
- Therapeutic targeting of the disease-associated signaling networks provides a reliable way for rational drug repurposing and rapid development of synergistic drug combinations for common human diseases.
- Here we demonstrate the feasibility and efficacy of the proposed approach with an experiment application to Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35811522) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Drug development
Also tagged “genetics”
346 studies in the library carry the topic tag “genetics”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 346 tagged studies.